Table 1.
Overview of MID3 themes, points, and counterpoints discussed at the 2019 ASCPT Annual Meeting
| Theme | Point (speaker abbreviations)a | Counterpoint (speaker abbreviations)a |
|---|---|---|
| 1. State of the art | MID3 has been a smashing success (J.G.) | No. MID3 has fallen short of expectations (O.D.P.) |
| 2. Primary limitations to success | Talk more, model less (S.T.) | Talk less, model more (O.D.P.) |
| 3. All models are wrong, but some are useful | Wrong models are dangerous (S.T.) | Wrong models are useful (P.H.v.d.G.) |
| 4. Transforming clinical trial design decision making | All clinical trials should be informed by simulations (M.R.G.) | Simulations are unnecessary and time consuming in most cases (D.O.) |
| 5. Disruptive innovations necessary for the future | Industrialize current models & methodologies (J.G.) | Future lies in machine learning and systems models (M.R.G.) |
| 6. The ideal MID3 scientist for the future | Best pharmacometricians have training in mathematics and statistics (D.A.) | Best pharmacometricians have training in medicine and pharmacology (P.H.v.d.G.) |
| 7. Organizational opportunities in R&D | Pharmacometricians have a strategic role and hence need to be part of the core development team (D.O.) | Pharmacometricians provide technical solutions but are not part of drug development teams (D.A.) |
MID3, model‐informed drug discovery and development; R&D, research and development.
a
Views expressed were to facilitate debate and did not always reflect personal opinion.